Homepage > Company > Media > Pharma News > 2021 > BioVaxys, BioElpida Collaborate to Produce Ovarian Cancer Vaccine

BioVaxys, BioElpida Collaborate to Produce Ovarian Cancer Vaccine

Vancouver, Canada-based BioVaxys Technology has struck a deal with BioElpida for production and aseptic packaging of BioVaxys’ ovarian cancer vaccine candidate, BXV-0918A, at its facility in Lyon, France.

BioVaxys is developing BVX-0918A with Spanish drugmaker ProCare Health Iberia, which expects to apply to the European Medicines Agency for compassionate use authorization later this year for stage 3/stage 4 ovarian cancer.

BioVaxys is also developing vaccines against ovarian cancer and the SARS-CoV-2 virus.

May 4, 2021

https://www.fdanews.com/

Read also

Spinogenix’s ALS hopeful to advance to registrational trial

Spinogenix’s first-in-class ALS treatment, SPG302 has been shown to slow disease progression in 82% of patients during a Phase IIa study.

FDA Approves First Treatment for Rare Thymidine Kinase 2 Deficiency

Thymidine kinase 2 deficiency (TK2d) is an ultra-rare (1.64 cases per 1,000,000 people) often fatal, genetic mitochondrial disease characterized by progressive and severe muscle weakne...

Cencora

Cencora to invest $1bn in US pharma distribution network

Celltrion

Celltrion Signs Licensing Deal with U.S. Kaigene for Two Antibody Drug Candidates